European Society of Cardiology Congress: PARADIGM-HF Discussion, 4 New Studies — Physician’s First Watch
European Society of Cardiology Congress: PARADIGM-HF Discussion, 4 New Studies
By the Editors
On CardioExchange, the authors of the groundbreaking PARADIGM-HF trial — presented over the weekend at the European Society of Cardiology Congress — answer questions from Harlan Krumholz and readers about how their results could change the management of heart failure.
Meanwhile, NEJM Journal Watch Cardiology shares its coverage of four additional trials presented at the meeting:
ATLANTIC: In patients with ST-segment elevation myocardial infarction (STEMI), reperfusion rates did not differ whether the antiplatelet ticagrelor was administered in the ambulance or in the cath lab.
SIGNIFY: Ivabradine lowered heart rate but did not improve outcomes among patients with stable coronary artery disease who did not have heart failure. (The drug is available in Europe but not the U.S.)
SOLID-TIMI 52: The investigational drug darapladib proved ineffective for secondary prevention after acute coronary events.
TASTE: A randomized trial provides strong evidence to skip the aspiration catheter before percutaneous coronary intervention for STEMI.